59 VX-950, a novel HCV protease inhibitor, retains potency against BILN-2061 resitant replicon cells: Computational analysis indicates that resistance develops via different mechanisms
Lin, C., Lin, K., Luong, Y.P., Rao, B.G., Wei, Y.Y., Brennan, D., Fulghum, J., Frantz, D., Hsiao, H.M., Ma, S., Maxwell, J., Perni, R.B., Gates, C.A., Kwong, A.D.
Published in Journal of hepatology (2004)
Published in Journal of hepatology (2004)
Get full text
Journal Article